A Study to Learn About the Investigational Medicine Called PF-06821497 (mevrometostat) in Men with mCRPC Who Were Previously Treated with Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Pfizer Inc.

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male

Therapeutic area

Not possible to specify

Trial duration

17 Jan 2025 → ongoing

Decision date (initial)

2024-12-11

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

External identifiers

EU CT number

2024-511650-50-00

ClinicalTrials.gov

NCT06551324

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Therapy, Efficacy, Safety, Pharmacokinetic

To demonstrate that PF-06821497 in combination with enzalutamide is superior to PCT of enzalutamide or docetaxel in prolonging rPFS.

Secondary objectives 6

1. To demonstrate that PF-06821497 in combination with enzalutamide is superior to PCT (enzalutamide or docetaxel) in prolonging OS.
2. To evaluate anti-tumor activity.
3. To compare safety and tolerability between the treatment arm and the control arm.
4. To compare patient reported outcomes (PROs) between the treatment arm and the control arm
5. To evaluate the PK of PF-06821497 when dosed with enzalutamide.
6. To assess the relationship between ctDNA burden and outcome.

Conditions and MedDRA coding

METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Study design 1 period

Regulatory references

Scientific advice from competent authorities

European Medicines Agency

Plan to share IPD

Yes

IPD plan description

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 7

1. Male Participants aged ≥18 years (or the minimum age of consent in accordance with local regulations) at screening.
2. Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features (neuroendocrine differentiation and other histologic components are permitted if adenocarcinoma is the primary histology). For participants without a prior histological diagnosis, a baseline de novo biopsy must be used to confirm the diagnosis.
3. Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
4. Surgically or medically castrated, with serum testosterone ≤50 ng/dL (≤1.73 nmol/L) at screening.
5. Progressive disease in the setting of surgical or medical castration as defined by 1 or more of the following 3 criteria:PSA progression defined as a minimum of two rising PSA levels with an interval of ≥1 week between each determination within the last 12 months. The PSA value at the Screening visit must be ≥1 ng/mL if confirmed rise in PSA is the only indication of progression per PCWG3 criteria;Soft tissue disease progression as defined by RECIST v1.1;Bone disease progression defined by PCWG3 with 2 or more new metastatic bone lesions on a whole-body radionuclide bone scan. d. Evidence of disease progression on treatment with at least 12 weeks of abiraterone acetate in the mCSPC setting or first line mCRPC setting is required. In the non-metastatic setting, evidence of disease progression during treatment (for at least 12 weeks) or within 3 months of treatment completion. In first line mCRPC, prior treatment with abiraterone acetate (for at least 12 weeks) in conjunction with olaparib or niraparib is permissible. e. Prior treatment with PARP monotherapy for BRCAm/HRRm gene mutated mCRPC following cancer progression on abiraterone acetate is not permissible.
6. Resolution of acute effects of any prior therapy to either baseline severity or CTCAE Grade ≤ 1 (except for AEs such as alopecia and peripheral neuropathy not constituting a safety risk in the investigator’s judgment).
7. ECOG performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.

Exclusion criteria 12

1. Any medical (including active or clinically significant bacterial, fungal or viral infection) or psychiatric condition including recent (within the past year) or active suicidal ideation/in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study.
2. Hematologic abnormalities defined as: ANC <1500/mm3; Platelets <100,000/μL; Hemoglobin <9 g/dL, independent of transfusion within 14 days of randomization
3. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
4. Clinically significant cardiovascular disease defined as: Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Class III or IV), cerebrovascular accident, or symptomatic pulmonary embolism or other clinically significant episode of thromboembolic disease, congenital long QT syndrome, Torsade de Pointes, clinically important arrhythmias, left anterior hemiblock (bifascicular block), ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2; Cardiac rhythm device/pacemaker; QTcF >480 msec on screening ECG.
5. CNS pathology/neurological findings: Known or suspected brain metastasis or active leptomeningeal disease; Symptomatic or impending spinal cord compression or cauda equina syndrome; Participants with epidural disease, canal disease and prior cord involvement are NOT excluded if those areas have been treated, are stable, and not neurologically impaired; Clinically significant history of seizure or any condition that may predispose to seizure (eg, prior cortical stroke, significant brain trauma). Also, history of unexplained loss of consciousness or transient ischemic attack within 12 months of randomization.
6. Any history of myelodysplastic syndrome, acute myeloid leukemia, or any other prior malignancy except for any of the following: Carcinoma in situ or non-melanoma skin cancer; Any prior malignancies ≥3 years before randomization with no subsequent evidence of recurrence or progression regardless of the stage; Stage 0 or Stage 1 cancer <3 years before randomization that has a remote probability of recurrence or progression in the opinion of the investigator.
7. Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (ie, 177Lu-PSMA-617, radium-223), ARSi (including enzalutamide, apalutamide, darolutamide), PARP monotherapy or other systemic anti-cancer treatment (approved drugs or experimental compounds such as, antibody therapy, immunotherapy, gene therapy, angiogenesis inhibitors, CDK4/6 inhibitors, 5-alpha reductase inhibitors, EZH2 inhibitors) with the following exceptions: a. Treatment with first-generation antiandrogen agents (eg, bicalutamide, nilutamide, and flutamide), but must be discontinued prior to the first dose of study medication.; b. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion; c. Current use of 5-alpha reductase inhibitors is prohibited within 28 days prior to randomization..
8. Current use or anticipated need for drugs that are known strong CYP3A4/5 inhibitors and inducers (with exception of enzalutamide as part of this study) outlined in Sections 6.9.1 and 6.9.2, including their administration within 10 days or 5 half-lives, whichever is longer prior to randomization.
9. Major surgery or palliative localized radiation therapy within 14 days before randomization.
10. Inadequate renal function defined by an eGFR <45 mL/min/1.73 m2. Based upon participant age at screening, eGFR is calculated using the recommended formulas in Section 10.7.1 to determine eligibility and to provide a baseline to quantify any subsequent kidney safety events. For eligibility assessment based upon estimated renal function, the higher of the screening and baseline eGFR values may be used.
11. Hepatic dysfunction defined as: Total bilirubin ≥1.5 × ULN; AST >2.5 × ULN; ALT >2.5 × ULN
12. Previous administration with an investigational product (drug or vaccine which does not meet exclusion criterion 5 above) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. BICR assessed rPFS per RECIST v1.1 (soft tissue disease) and PCWG3 (bone disease).

Secondary endpoints 17

1. OS (alpha protected).
2. Proportion of participants with measurable soft tissue disease at baseline with an objective response per RECIST v1.1 (assessed by BICR).
3. Duration of response in soft tissue disease per RECIST v1.1 (assessed by BICR).
4. Proportion of participants with PSA response ≥50% in participants with detectable PSA values at baseline.
5. Time to PSA progression.
6. Time to initiation of new antineoplastic therapy.
7. Time to first symptomatic skeletal event.
8. PFS2 based on investigator assessment
9. Type, incidence, severity (as graded by NCI CTCAE v5.0), seriousness and relationship to study medications of AEs.
10. Change from baseline in patient reported pain symptoms per BPI-SF
11. Change from baseline in HRQoL, functioning and symptoms per FACT-P
12. Change from baseline in patient reported health status per EQ-5D-5L
13. Symptomatic toxicity and the overall side effect burden as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE) and FACT-GP5
14. Time to confirmatory deterioration in patient-reported pain symptoms per BPISF Item 3 “worst pain in 24 hours”
15. Time to definitive deterioration in patientreported HRQoL and physical well-being per FACT-P.
16. PK characterized by pre-dose trough and post-dose plasma concentrations of PF- 06821497 at selected visits.
17. ctDNA burden at baseline and on study.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Comparator 2

Auxiliary 3

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pfizer Inc.

Sponsor organisation

Pfizer Inc.

Address

66 Hudson Boulevard East

City

New York

Postcode

10001-2189

Country

United States

Scientific contact point

Organisation

Pfizer Inc.

Contact name

Clinical Medical Lead

Public contact point

Organisation

Pfizer Inc.

Contact name

Clinical Medical Lead

Third parties 10

Locations

11 EU/EEA countries · 59 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 172 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

7 submissions — initial application plus substantial / non-substantial modifications